Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients
- PMID: 1695407
- DOI: 10.1016/0166-2236(90)90113-o
Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients
Abstract
In patients affected by Parkinson's disease, and in the monkey model of this disease, visual defects have been shown using psychophysical and electrophysiological measures of spatial and temporal contrast sensitivity. These studies imply an essential role for dopamine in primate vision. There is electrophysiological and neurochemical evidence to suggest that at least part of the problem is impaired retinal processing caused by systemic dopaminergic deficiency. Some of the deficits that have been demonstrated, consistent with physiological studies, suggest that center-surround interaction of neurons may suffer as a consequence of dopaminergic deficiency. The role of the regulation of retinal dopamine (D1 and D2) receptors in primate vision and of the balance of these receptors in presynaptic dopaminergic deficiency is not yet determined. Using sinusoidal grating stimuli in cognitively loaded tasks may increase understanding of the behavioral consequences of visual deficits seen in dopamine deficiency syndromes.
Similar articles
-
The visual system in Parkinson's disease.Res Publ Assoc Res Nerv Ment Dis. 1990;67:297-316. Res Publ Assoc Res Nerv Ment Dis. 1990. PMID: 2106154 Review. No abstract available.
-
Visual dysfunction in Parkinson's disease.Clin Neurosci. 1998;5(2):102-6. Clin Neurosci. 1998. PMID: 10785835 Review.
-
Dopaminergic modulation of visual sensitivity in man.Fundam Clin Pharmacol. 1993;7(8):449-63. doi: 10.1111/j.1472-8206.1993.tb01041.x. Fundam Clin Pharmacol. 1993. PMID: 8294083 Review.
-
Abnormal psychophysical visual perception in Parkinson's disease patients.Acta Neurol Belg. 2003 Jun;103(2):83-7. Acta Neurol Belg. 2003. PMID: 12892001 Review.
-
An electrophysiological study of D2 dopaminergic actions in normal human retina: a tool in Parkinson's disease.Neurosci Lett. 1992 Jun 8;140(1):125-8. doi: 10.1016/0304-3940(92)90697-6. Neurosci Lett. 1992. PMID: 1407691
Cited by
-
Potential role of retina as a biomarker for progression of Parkinson's disease.Int J Ophthalmol. 2011;4(4):433-8. doi: 10.3980/j.issn.2222-3959.2011.04.21. Epub 2011 Aug 18. Int J Ophthalmol. 2011. PMID: 22553695 Free PMC article.
-
Apomorphine induced cognitive changes in Parkinson's disease.J Neurol Neurosurg Psychiatry. 1994 Aug;57(8):998-1001. doi: 10.1136/jnnp.57.8.998. J Neurol Neurosurg Psychiatry. 1994. PMID: 8057129 Free PMC article. Clinical Trial.
-
Visual hallucinosis: the major clinical determinant of distorted chromatic contour perception in Parkinson's disease.J Neural Transm (Vienna). 1996;103(10):1195-204. doi: 10.1007/BF01271204. J Neural Transm (Vienna). 1996. PMID: 9013406
-
Comparative Analysis of Tyrosine Hydroxylase Amacrine Cells in the Mammalian Retina: Distribution and Quantification in Mouse, Rat, Ground Squirrel and Macaque Retinas.Int J Mol Sci. 2025 Jul 20;26(14):6972. doi: 10.3390/ijms26146972. Int J Mol Sci. 2025. PMID: 40725219 Free PMC article.
-
Remodeling of the fovea in Parkinson disease.J Neural Transm (Vienna). 2013 May;120(5):745-53. doi: 10.1007/s00702-012-0909-5. Epub 2012 Dec 23. J Neural Transm (Vienna). 2013. PMID: 23263598
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical